Indegene IPO Opens May 6: Rs 1,842 Crore Offer

By By Rediff Money Desk, NEWDELHI
Apr 29, 2024 14:55
Indegene, a healthcare tech firm, has fixed the price band for its Rs 1,842-crore IPO at Rs 430-452 per share. The offer opens on May 6 and concludes on May 8.
Illustration: Dominic Xavier/Rediff.com
New Delhi, Apr 29 (PTI) Indegene Ltd, a healthcare tech firm focused on the global life sciences industry, on Monday said it has fixed the price band at Rs 430 to Rs 452 per share for its Rs 1,842-crore initial share-sale offer that opens for public subscription on May 6.

The initial public offering (IPO) will conclude on May 8. The bidding for anchor investors will open for a day on May 3, the company announced.

The company's IPO comprises a fresh issue of equity shares worth up to Rs 760 crore and an Offer For Sale (OFS) of up to 2.34 crore equity shares aggregating Rs 1,082 crore, at the higher end of the price band, by selling shareholders. This takes the total IPO size to 1,842 crore.

The OFS would see sale of shares by existing investors CA Dawn Investments, a Carlyle group entity, Vida Trustees in its capacity as partner of Group Life Spring, Brighton Park Capital's entities BPC Genesis Fund I SPV Ltd, and BPC Genesis Fund I-A SPV Ltd, and individual investors Manish Gupta, Rajesh Bhaskaran Nair, and Anita Nair.

At present, Nadathur Fareast Pte Ltd is the biggest shareholder in Indegene with a 23.64 per cent stake. CA Dawn Investments has a 20.42 per cent stake, and Brighton Park Capital owns a 12 per cent stake in the company.

Funds raised through the fresh issue would be used to pay debt, funding capital expenditure requirements, payment of deferred consideration for one of its past acquisitions, funding inorganic growth and general corporate purposes.

Indegene had raised USD 200 million from Carlyle Group and Brighton Park Capital in February 2021.

Founded in 1998, Indegene offers solutions that help enable biopharmaceutical, emerging biotech and medical devices companies to develop products, launch them in the market, and drive sales throughout their life cycle.

Kotak Mahindra Capital, Citigroup Global Markets India, J P Morgan India, Nomura Financial Advisory and Securities (India) are the book running lead managers to the issue.
Read More On:
indegene ipoipohealthcare techlife sciencesindegene ltd
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

Samsung Galaxy S25: India Manufacturing, AI...

Samsung's new Galaxy S25 series will be manufactured in India, boasts enhanced AI...

Maharashtra Inks Rs 15 Lakh Cr MoUs at Davos

Maharashtra government signs 54 MoUs worth Rs 15.70 lakh crore at Davos, including a Rs...

Karnataka Unveils New Industrial, EV Policies...

Karnataka will announce new industrial, EV and clean mobility policies at the Karnataka...

Responsible AI Challenges: HCLTech-MIT Study

HCLTech and MIT study reveals challenges in adopting responsible AI, highlighting...

Go Digit Q3 Net Profit Soars 3-fold to Rs 119...

Go Digit's net profit for Q3 FY25 surged by almost 300% to Rs 119 crore, driven by...

India's Digital Potential: Key to Inclusive...

KPMG report highlights India's digital potential for inclusive growth and becoming a...

JSW UAV to Set Up Rs 800 Crore Facility in...

JSW UAV Ltd. has signed an MoU with the Telangana government to establish a...

India Aims for 10,000 GI Products by 2030

India's Commerce Minister sets an ambitious target to register 10,000 Geographical...

Wadhawan Port: India Aims for Top 10 Container...

Union Minister Sonowal highlights Wadhawan Port's potential to elevate India to the top...

HUDCO Q3 Net Profit Surges 42% to Rs 735 Cr

HUDCO's consolidated net profit for the December quarter rose 42% to Rs 735.03 crore,...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com